What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Myeloid leukemia, Leukemia, Fms-Like Tyrosine Kinase 3, Cancer research and Quizartinib.
His work deals with themes such as Lestaurtinib, Pharmacology and Tyrosine-kinase inhibitor, which intersect with Myeloid leukemia.
The various areas that Mark J. Levis examines in his Lestaurtinib study include Sunitinib and Targeted therapy.
His Leukemia study integrates concerns from other disciplines, such as Chemotherapy, Myeloid and CD34, Stem cell, CD38.
His research investigates the connection between Fms-Like Tyrosine Kinase 3 and topics such as Surgery that intersect with issues in Sorafenib, Cumulative incidence and Tolerability.
His Cancer research study incorporates themes from Mutation, Tyrosine kinase, FLT3 Inhibitor and Receptor tyrosine kinase.
His most cited work include:
- Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia (566 citations)
- Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia (566 citations)
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) (441 citations)
What are the main themes of his work throughout his whole career to date?
Mark J. Levis mainly focuses on Myeloid leukemia, Internal medicine, Cancer research, Leukemia and Oncology.
His research in Myeloid leukemia intersects with topics in Quizartinib, Fms-Like Tyrosine Kinase 3 and Sorafenib.
His Fms-Like Tyrosine Kinase 3 research integrates issues from Targeted therapy, FLT3 Inhibitor and FLT3 Internal Tandem Duplication.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine.
His studies in Cancer research integrate themes in fields like Mutation, Tyrosine kinase, Receptor tyrosine kinase and Tyrosine-kinase inhibitor.
His studies examine the connections between Leukemia and genetics, as well as such issues in Pharmacology, with regards to In vivo.
He most often published in these fields:
- Myeloid leukemia (51.05%)
- Internal medicine (50.15%)
- Cancer research (33.63%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (50.15%)
- Myeloid leukemia (51.05%)
- Oncology (26.73%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Myeloid leukemia, Oncology, Cancer research and Leukemia.
As a part of the same scientific family, Mark J. Levis mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Myeloproliferative neoplasm and Graft-versus-host disease.
His Myeloid leukemia research incorporates themes from Quizartinib, Cancer, Incidence and Cohort.
His Oncology research includes themes of MRD Negative, Dasatinib, Sorafenib, Neutropenia and Allogeneic transplantation.
His Cancer research study combines topics from a wide range of disciplines, such as Tyrosine kinase, FLT3 Inhibitor and Maintenance therapy.
His studies in Leukemia integrate themes in fields like Myeloid, White blood cell, Fibrinogen and Hemoglobin.
Between 2019 and 2021, his most popular works were:
- A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. (13 citations)
- The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. (9 citations)
- Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study (6 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Myeloid leukemia, Oncology, Leukemia and Gastroenterology.
His Midostaurin study, which is part of a larger body of work in Myeloid leukemia, is frequently linked to CYP3A, bridging the gap between disciplines.
His Midostaurin study contributes to a more complete understanding of Cancer research.
He combines subjects such as Gilteritinib and Minimal residual disease with his study of Oncology.
His research brings together the fields of Myeloid and Leukemia.
The Gastroenterology study combines topics in areas such as Chemotherapy and Transplantation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
